Latest News

FDA Approves Lundbeck’s VYEPTI™ (eptinezumab-jjmr) – The First and Only Intravenous Preventive Treatment for Migraine

DEERFIELD, Ill.–(BUSINESS WIRE)–Lundbeck announced that VYEPTI™ (eptinezumab-jjmr) has been approved by the U.S. FDA for the preventive treatment of migraine in adults.

Source link

Related posts

Antidepressants can be used to treat Alzheimer’s disease


NHS commissioners are ignoring guidelines by rationing cataract surgery


Where Is Your Risk of Dying Greatest After Surgery?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World